SHH and medulloblastoma: Research established the viability of using ctDNA-based liquid biopsy to monitor medulloblastoma mutations, highlighting that TP53 mutations within sonic hedgehog (SHH)-activated (group 2) subtypes correlate with treatment failures and unfavorable survival rates [57].